Search results
Results from the WOW.Com Content Network
Cold boxes are typically used to carry vaccines around the area. It is a self-supporting container with insulation and ice-packs surrounding the interior to keep vaccines at low temperatures. [22] Unlike the refrigerator, the cold box has limited time to maintain temperatures below +10 °C, normally 48–96 hours. [23]
GVAX is a cancer vaccine composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), and then irradiated to prevent further cell division.
CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. [2] The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba, and made available to the Cuban population in 2011.
Maintenance of vaccine quality is the shared responsibility of all handlers of vaccines from the time a vaccine is manufactured until administration. According to the Immunization Action Coalition , all vaccines should be stored in a refrigerator or freezer that is designed specifically for the storage of biologics or, alternatively, in a ...
To produce viral vaccines, candidate vaccine viruses are grown in mammalian, avian or insect tissue culture of cells with a finite lifespan. [5] These cells are typically Madin-Darby Canine Kidney cells, [6] but others are also used including monkey cell lines pMK and Vero and human cell lines HEK 293, MRC 5, Per.C6, PMK, and WI-38. [7]
NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials. [6] As a result, two additional NeuVax trials registered or underway are: (1) a 700 patient Phase 3 trial for FDA approval - not yet recruiting [2] [needs update] and (2) a 300 patient Phase 2 trial studying the combination of ...
A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. [1] Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.
David Matthews, a co-author for this study, clarified that MRC-5 was solely used for testing purposes to determine "how the Oxford vaccine behaves when it is inside a genetically normal human cell." [ 6 ] The manufacturing of the vaccine used the HEK 293 fetal cell line, the kidney cells of an aborted or spontaneously miscarried female fetus ...